黑料吃瓜群网

Women undergoing operations are not being routinely informed that a common anaesthetic may make their contraception efforts less effective, according to UK doctors.

The drug, sugammadex, is widely used in anaesthesia and is known to interact with the hormone progesterone, a main component of hormonal contraceptives, including the pill, implants and IUDs. Administered towards the end of the operation, ahead of waking the patient up, the drug reverses the action of drugs given earlier in the procedure to relax the patient鈥檚 muscles.

The researchers surveyed 150 health professionals in a UK hospital and found that 70% of the respondents said they do not routinely discuss the drug interaction with their patients. Additionally, of the 48 patients given聽sugammadex while on a hormonal contraceptive during the researchers鈥� six-week audit, none had medical records referring to have spoken about it. This is according to research presented at Euroanaesthesia, the annual meeting of the European Society of Anaesthesiology and Intensive Care (ESAIC) in Milan, Italy.

Current guidance is to inform women of child-bearing age (WCBA) that they have received the drug and, due to increased risk of contraceptive failure, advise those taking oral hormonal contraceptives to follow the missed pill advice in the leaflet that comes with their contraceptives and advise those using other types of hormonal contraceptive to use an additional non-hormonal means of contraception for seven days.¹

In the experience of the authors, robust methods for identifying at-risk patients and informing them of the associated risk of contraceptive failures is not common practice across anaesthetic departments within the UK, and likely further afield. To find out more, Dr Neha Passi, Dr Matt Oliver and colleagues at the Department of Anaesthesiology, University College London 黑料吃瓜群网s NHS Foundation Trust, London, UK, surveyed consultants, junior doctors and physician assistants. 94% of the 82 anaesthetists who responded said they were aware of the risk of contraceptive failure. 70% of respondents said they do not routinely discuss sugammadex with the patients who have received the drug. 234 patients were administered sugammadex during the six weeks covered by the audit. 65 (28%) of the patients given sugammadex were WCBA and 48 of these should have received advice on the risks of contraceptive failure. There was no record of it, however, in the medical notes of any of the 48 women. (The other 17鈥檚 medical history meant they weren鈥檛 at risk of pregnancy and so not eligible for the advice.)

Dr Passi said, 鈥淚t is concerning that we are so seldom informing patients of the risk of contraceptive failure following sugammadex use.

鈥淯se of sugammadex is expected to rise as it becomes cheaper in the future, and ensuring that women this receiving medicine are aware it may increase their risk of unwanted pregnancy must be a priority.鈥�

鈥淲e only studied one hospital trust but we expect the results to be similar elsewhere in the UK,鈥� Dr Oliver said.

Dr Passi said it is important to note, however, that most patients receiving an anaesthetic do not need a muscle relaxant² and that sugammadex is one of several drugs available to reverse muscle relaxation.

In response to their findings, the study鈥檚 authors have created patient information leaflets and letters and programmed the Trust鈥檚 electronic patient record system to identify 鈥榓t-risk鈥� patients and deliver electronic prompts to the anaesthetists caring for them in the perioperative period. Sugammadex is the only anaesthetic drug known to have this effect, according to the doctors.

References:

^{1. www.ema.europa.eu/en/documents/product-information/bridion-epar-product-information_en.pdf}

^{2. https://www.nationalauditprojects.org.uk/NAP5report?newsid=1187#pt (chapter 19)}

Image credit: 漏stock.adobe.com/au/Kaspars Grinvalds